Manganese-DPDP as a Hepatobiliary Contrast Agent in the Magnetic Resonance Imaging of Liver Tumors: Results of Clinical Phase II Trials in Germany Including 141 Patients

Rummeny, Ernst J.; Ehrenheim, C.; Gehl, Hans-Björn; Hamm, Bernd; Laniado, Michael; Lodemann, Klaus‐Peter; Schmiedel, E.; Steudel, A.; Vogl, Th.

doi:10.1097/00004424-199111001-00048

Cited by 60 publications

(25 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: Mangafodipir Trisodiummentioning

confidence: 97%

“…Post-injection images obtained 20-60 min after administration provided more diagnostic information than unenhanced images in up to 68% [20]. A dosage of 10 µmol kg −1 was superior to 5 µmol kg −1 in terms of tumour-liver contrast, without increasing the rate of adverse events [20]. However, mangafodipir trisodium at 5 µmol kg −1 improved liver tumour contrast by 46.2-79.8% on T1w SE and by 86.6-137.5% on T1w GRE images in a phase-2 study [38].…”

Section: Mangafodipir Trisodiummentioning

confidence: 98%

“…However, facial flushing was not significantly increased when slow bolus injection over 2-2.5 min was used instead of infusion over 10-20 min [19]. In general, it has been shown that mangafodipir is a safe agent at a dosage of 5 µmol kg −1 body weight [20].…”

Section: Mangafodipir Trisodiummentioning

confidence: 99%

See 2 more Smart Citations

Hepatobiliary contrast agents for contrast-enhanced MRI of the liver: properties, clinical development and applications

2004

View full text Add to dashboard Cite

Hepatobiliary contrast agents with uptake into hepatocytes followed by variable biliary excretion represent a unique class of cell-specific MR contrast agents. Two hepatobiliary contrast agents, mangafodipir trisodium and gadobenate dimeglumine, are already clinically approved. A third hepatobiliary contrast agent, Gd-EOB-DTPA, is under consideration. The purpose of this review is to provide an overview on the properties, clinical development and application of these three hepatobiliary contrast agents. Bolus injectable paramagnetic hepatobiliary contrast agents combine established features of extracellular agents with the advantages of hepatocyte specificity. The detection and characterisation of focal liver disease appears to be improved compared to unenhanced MRI, MRI with unspecific contrast agents and contrast-enhanced CT. To decrease the total time spent by a patient in the MR scanner, it is advisable to administer the agent immediately after acquisition of unenhanced T1-w MRI. After infusion or bolus injection (with dynamic FS-T1-w 2D or 3D GRE) of the contrast agent, moderately and heavily T2w images are acquired. Post-contrast T1-w MRI is started upon completion of T2-w MRI for mangafodipir trisodium and Gd-EOB-DTPA as early as 20 min following injection, while gadobenate dimeglumine scans are obtained >60 min following injection. Post-contrast acquisition techniques with near isotropic 3D pulse sequences with fat saturation parallel the technical progress made by MSCT combined with an unparalleled improvement in tumour-liver contrast. The individual decision that hepatobiliary contrast agent one uses is partly based on personal preferences. No comparative studies have been conducted comparing the advantages or disadvantages of all three agents directly against each other.

show abstract

Section: Mangafodipir Trisodiummentioning

confidence: 97%

Section: Mangafodipir Trisodiummentioning

confidence: 98%

See 1 more Smart Citation

Hepatobiliary contrast agents for contrast-enhanced MRI of the liver: properties, clinical development and applications

2004

View full text Add to dashboard Cite

show abstract

“…The first large series conducted with this agent was reported in 1991. It was a phase II trial that included 141 patients among which 38 (27%) exhibited minor side effects [24]. Flushing and warmth were reported in 21/141 patients (14%), and nausea in three (2.1%).…”

Section: Manganese Based Contrast Agentsmentioning

confidence: 99%

Safety of MR liver specific contrast media

et al. 2004

View full text Add to dashboard Cite

Over the past few years a number of magnetic resonance (MR) liver specific contrast agents have been introduced. In this report the safety issues of these agents are addressed. A literature search was carried out. Based on the available information, simple guidelines on the safety issue of liver specific contrast agents have been produced by the Contrast Media Safety Committee of the European Society of Urogenital Radiology. The report and guidelines were discussed at the 11th European Symposium on Urogenital Radiology in Santiago de Compostela. Liver specific contrast agents appear in general to be safe and well tolerated. However, the incidence of adverse reactions with iron oxides and the intravenous manganese based agent seems to be slightly higher than with gadolinium based agents. However, no safety information from comparative clinical trials has been published. Guidelines on the safety aspects are presented.

show abstract

“…Thus Mn-DPDP is a potential candidate for specific hepatocyte uptake by the pyridoxine transporter at the sinusoidal pole [5][6][7][8]. The pyridoxine transporters that exist in the hepatocyte can selectively recognize, bind to pyridoxamine, and be transported into hepatocyte.…”

mentioning

confidence: 99%

Study on the Anticancer Drug 5-Fluorouracil-Conjugated Polyaspartamide Containing Hepatocyte-Targeting Group

Yan

Zhuo

Zheng

2001

Journal of Bioactive and Compatible Polymers

View full text Add to dashboard Cite

Anticancer conjugates of 5-fluorouracil (5-Fu) and polyaspartamide, containing pyridoxamine as the hepatocyte-targeting group, were synthesized and characterized. Their sustained release properties and biodistribution were evaluated. The 5-Fu was targeted to specific organs, such as the liver, and had a sustained in vitro release rate in PBS. In vitro cytotoxicity assay showed that the polymeric drugs exhibited low cytotoxicity to the human liver cells (L-02). These polymeric drugs possess high anticancer efficiencies and induced apoptosis in the human hepatic tumor cells (Bel-7204). INTRODUCTIONP olymer-based drug delivery systems are used to optimize the therapeutic properties of drugs and render them safer, effective and reliable [1]. Moreover, polymeric drugs and macromolecules used as drug carriers can be easily synthesized at low cost, freely water-soluble, non-toxic, non-immunogenic and well characterized from the physico-chemical point of view [2,3].

show abstract

Manganese-DPDP as a Hepatobiliary Contrast Agent in the Magnetic Resonance Imaging of Liver Tumors: Results of Clinical Phase II Trials in Germany Including 141 Patients

Cited by 60 publications

References 0 publications

Hepatobiliary contrast agents for contrast-enhanced MRI of the liver: properties, clinical development and applications

Hepatobiliary contrast agents for contrast-enhanced MRI of the liver: properties, clinical development and applications

Safety of MR liver specific contrast media

Study on the Anticancer Drug 5-Fluorouracil-Conjugated Polyaspartamide Containing Hepatocyte-Targeting Group

Contact Info

Product

Resources

About